Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.76 |
| ▸ | NPC1 | O15118 | 3/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | AXL | P30530 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SCN4A | P35499 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.50 |
| ▸ | PI4KA | P42356 | 6/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 6/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9762807 | 0.90 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL8656868 | 0.89 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL2445933 | 0.88 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL5946675 | 0.88 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL8500947 | 0.88 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL142514 | 0.86 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL9722768 | 0.83 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2MAPTCYP3A4 | |
| Hydrochloric Acid SCHEMBL7331641 | 0.83 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL13780339 | 0.82 | RAB9A (0.81) | RAB9ANPC1SMN1; SMN2MAPTCYP3A4 | |
| SCHEMBL13273315 | 0.81 | SMN1; SMN2 (0.54) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0866703-A1 | USE OF 2-AMINOBENZOTHIAZOLES FOR TREATING PARKINSON'S DISEASE AND PARKINSONIAN SYNDROMES | Aventis Pharma S.A. (FR) | 1998-09-30 | — | — | EP | claimed |
| WO-1997020557-A1 | USE OF 2-AMINOBENZOTHIAZOLES FOR TREATING PARKINSON'S DISEASE AND PARKINSONIAN SYNDROMES | RHONE-POULENC RORER S.A. (FR) | 1997-06-12 | — | — | WO | claimed |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| WO-2023225252-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-3943488-A1 | SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2022-01-26 | — | — | EP | disclosed |
| WO-2021066573-A1 | NOVEL COMPOUND AND USE THEREOF IN TREATING AUTOIMMUNE DISEASES | 파렌키마바이오텍 주식회사 | 2021-04-08 | — | — | WO | disclosed |
| WO-2019183600-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-26 | — | — | WO | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20150011528-A1 | PHENYLIMIDE-CONTAINING BENZOTHIAZOLE DERIVATIVE OF ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2015-01-08 | — | — | US | disclosed |
| EP-1996180-B1 | BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD (GB) | 2011-08-03 | — | — | EP | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| EP-1996180-A1 | ANTIBACTERIAL AGENTS | Prolysis Limited (GB) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
| EP-0866703-A1 | USE OF 2-AMINOBENZOTHIAZOLES FOR TREATING PARKINSON'S DISEASE AND PARKINSONIAN SYNDROMES | Aventis Pharma S.A. (FR) | 1998-09-30 | — | — | EP | disclosed |
| WO-1997020557-A1 | USE OF 2-AMINOBENZOTHIAZOLES FOR TREATING PARKINSON'S DISEASE AND PARKINSONIAN SYNDROMES | RHONE-POULENC RORER S.A. (FR) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | ALK, ARG1, ROS1 | RAB9A 1340/4885NPC1 1786/4885SMN1; SMN2 2959/4885 |
| US-20150011528-A1 | PHENYLIMIDE-CONTAINING BENZOTHIAZOLE DERIVATIVE OF ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ILK, PKMYT1, PLAUR | RAB9A 916/4885NPC1 1984/4885SMN1; SMN2 2126/4885 |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | RAB9A 2799/4885NPC1 1400/4885SMN1; SMN2 1208/4885 |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | RAB9A 2799/4885NPC1 1400/4885SMN1; SMN2 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.